Radiology - Technology Information Portal
Sunday, 24 November 2024
• Welcome to Radiology-TIP.com!
     • Sign in / Create account
 
 'Contrast Agent' p12
SEARCH   
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Searchterm 'Contrast Agent' found in 5 terms [
] and 79 definitions [
]
Result Pages :
Hypaque 76
Hypaque 76 is a radiopaque contrast agent supplied as a 76 percent sterile aqueous solution providing 66 percent (w/v) diatrizoate meglumine and 10 percent (w/v) diatrizoate sodium.

Drug Information and Specification
NAME OF COMPOUND
Diatrizoate meglumine, diatrizoate sodium
MANUFACTURER
INDICATION
Urography, angiography, CT head
APPLICATION
Intravascular
PHARMACOKINETIC
Renal excretion
CHEMICAL BOND
2016 mosm/kgH2O
IODINE CONCENTRATION
370 mg/mL
50 mL to 125 mL
PREPARATION
Ready-to-use product
STORAGE
Protect from light. Store at 15°Celsius to 30°C (59° Fahrenheit to 86°F).
PRESENTATION
50 mL vials, 200 mL bottles
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
GE Healthcare has discontinued Hypaque 76 for unknown reasons.
Hypaque Meglumine
Hypaque Meglumine is an ionic contrast agent. Hypaque Meglumine 60 percent (w/v) is an aqueous solution containing 60 g of the meglumine salt of diatrizoic acid per 100 mL of solution.
The degree of contrast enhancement at computed tomography is directly related to the amount of iodine administered. In adults the amount of iodine usually required for contrast enhancement ranges from 28 to 42 g.
Hypaque Meglumine is also available in concentrations of 18% and 30%.

Drug Information and Specification
NAME OF COMPOUND
Diatrizoate meglumine
MANUFACTURER
INDICATION
Urography, angiography, CT head
APPLICATION
Intravascular
PHARMACOKINETIC
Renal excretion
CHEMICAL BOND
1415 mosm/kgH2O
IODINE CONCENTRATION
282 mg/mL
50 - 100 mL bolus injection, up to 150 mL by infusion
PREPARATION
Ready-to-use product
STORAGE
Protect from light. Store at 15°Celsius to 30°C (59° Fahrenheit to 86°F).
PRESENTATION
50 and 100 mL vials, 200 mL bottles
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Hypaque Sodium
Hypaque Sodium is a high-osmolar, water-soluble contrast agent. In pure form, it contains 59.87 percent organically bound iodine.
The dosage of contrast media is depended on the type of radiological procedure and should be tailored individually according to age, body size, and indication for examination.

Drug Information and Specification
NAME OF COMPOUND
Diatrizoate sodium
MANUFACTURER
INDICATION
Urography, angiography, CT head
APPLICATION
Intravascular
PHARMACOKINETIC
Renal excretion
CHEMICAL BOND
1515 mosm/kgH2O
IODINE CONCENTRATION
300 mg/mL
CT DOSAGE
50 - 100 mL, up to 150 mL by infusion
PREPARATION
Ready-to-use product
STORAGE
Protect from light. Store at 15°Celsius to 30°C (59° Fahrenheit to 86°F).
PRESENTATION
50 mL vials
DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Idiosyncratic Reactions
Patents can unintended respond with an idiosyncratic reaction to the application of contrast media. Idiosyncratic reactions to contrast agents start usually within 20 minutes after injection and occur more frequently in patients 20 to 40 years old.
Idiosyncratic reactions may or may not be dependent on the amount of dose injected, the speed of injection, the mode of injection and the radiographic procedure.

The minor symptoms are self-limited and of short duration and include:
scattered urticaria, pruritus, rhinorrhea, nausea, vomiting, diaphoresis, coughing, and dizziness.
Patients with minor symptoms should be observed for the progression or evolution of more severe reaction, which requires treatment.
Intermediate symptoms include:
diffuse urticaria, headache, persistent vomiting, facial edema, laryngeal edema, mild bronchospasm or dyspnea, palpitations, tachycardia, or bradycardia; hypertension; and abdominal cramps.
Intermediate symptoms require treatment and should be observed for progression.
Severe reactions include life-threatening symptoms:
arrhythmias (ventricular tachycardia), hypotension, overt bronchospasm, laryngeal edema, pulmonary edema, seizures and syncope.
Severe reactions are life-threatening and treatment is urgent and mandatory to prevent death.

See also Adverse Reaction and Anaphylactoid Reaction.
Image Quality
Image quality is an important value of all radiographic imaging procedures. Accurate measures of both image quality and patient radiation risk are needed for effective optimization of diagnostic imaging. Images are acquired for specific purposes, and the result depends on how well this task is performed. The imaging performance is mainly influenced by the imaging procedure, examined object, contrast agents, imaging system, electronic data processing, display, maintenance and the operator. Spatial resolution (sharpness), contrast resolution and sensitivity, artifacts and noise are indicators of image quality.
A high image contrast provides the discrimination between tissues of different densities.
The image resolution states the distinct visibility of linear structures, masses and calcifications.
Noise and artifacts degrade the image quality. In computed tomography (CT), high spatial resolution improves the visibility of small details, but results in increased noise. Increased noise reduces the low contrast detectability. Noise can be reduced by the use of large voxels, increased radiation dose, or an additional smoothing filter, but this type of filter increases blurring.
An image acquisition technique taking these facts into account maximizes the received information content and minimizes the radiation risk or keeps it at a low level.

See also As Low As Reasonably Achievable.
Result Pages :
 
Share This Page
Facebook
Twitter
LinkedIn
Look
      Ups
Radiology - Technology Information Portal
Member of SoftWays' Medical Imaging Group - MR-TIP • Radiology-TIP • Medical-Ultrasound-Imaging
Copyright © 2008 - 2024 SoftWays. All rights reserved.
Terms of Use | Privacy Policy | Advertising
 [last update: 2023-11-06 02:01:00]